



The Nutrition Society 23rd Annual Irish Section Postgraduate Meeting was held at University College,
Dublin on 13–14 February 2014

Irish postgraduate winners

Optimal vitamin D levels in Crohn's disease: a review

Tara Raftery and Maria O'Sullivan*

Department of Medicine, Trinity Centre for Health Science, St. James's Hospital, Dublin 8, Ireland

Vitamin D deficiency is common among patients with Crohn's disease. Serum 25-hydroxyvitamin D (25(OH)D) is the best measure of an individual's vitamin D status and current cut-off ranges for sufficiency are debatable. Several factors contribute to vitamin D deficiency in Crohn's disease. These include inadequate exposure to sunlight, inadequate dietary intake, impaired conversion of vitamin D to its active metabolite, increased catabolism, increased excretion and genetic variants in vitamin D hydroxylation and transport. The effects of low 25(OH)D on outcomes other than bone health are understudied in Crohn's disease. The aim of the present review is to discuss the potential roles of vitamin D and the possible levels required to achieve them. Emerging evidence suggests that vitamin D may have roles in innate and adaptive immunity, in the immune-pathogenesis of Crohn's disease, prevention of Crohn's disease-related hospitalisations and surgery, in reducing disease severity and in colon cancer prevention. The present literature appears to suggest that 25(OH)D concentrations of ≥ 75 nmol/l may be required for non-skeletal effects; however, further research on optimal levels is required.

Crohn's disease: 25-hydroxyvitamin D: Vitamin D levels: Inflammation

Crohn's disease and ulcerative colitis are immune-mediated idiopathic diseases of the gastrointestinal tract. Crohn's disease can involve the entire gastrointestinal tract, while ulcerative colitis is isolated to the colon and rectum, both conditions are collectively referred to as inflammatory bowel disease (IBD)⁽¹⁾. The key pathological mechanism in both cases is thought to be a dysregulated host immune response to commensal intestinal flora in genetically susceptible individuals^(2,3). Almost 100 genetic loci are currently associated with IBD, yet they incompletely explain the variance in disease incidence, suggesting a strong role for environmental factors, as supported by epidemiological data^(3–5).

Vitamin D has long been recognised as a major regulator of calcium and phosphorus metabolism and thus has key roles in bone formation and resorption^(6–8). Low bone mineral density is a common manifestation in Crohn's disease^(9,10) and guidelines regarding supplementation are well established⁽¹¹⁾. Despite this vitamin D insufficiency remains common. With the discovery of the vitamin D receptor (VDR) in numerous

tissues throughout the body beyond bone, including immune cells, a strong interest in understanding the role of vitamin D in disease pathogenesis and as a possible therapy in Crohn's disease has emerged^(12–15). The aim of the present review is to discuss vitamin D insufficiency in Crohn's disease, the potential benefits of supplementation and possible serum levels required to achieve the same.

Vitamin D physiology

Vitamin D metabolism

Vitamin D is a precursor of the active hormone calcitriol (1,25(OH)₂D) and is present in two forms; vitamin D₃ (cholecalciferol), which is the physiological form, and the synthetic analogue of vitamin D₂ (ergocalciferol). In human subjects, vitamin D can be obtained from two sources; diet and UVB exposure. Dietary sources of vitamin D₂ include irradiated yeast, plants and fungi, whereas vitamin D₃ is found in fish liver oils,

Abbreviations: CDAI, Crohn's disease activity index; IBD, inflammatory bowel disease; 1,25(OH)₂D, calcitriol; 25(OH)D, 25-hydroxyvitamin D; QoL, quality of life; VDR, vitamin D receptor.

*Corresponding author: Professor M. O'Sullivan, fax +353 1 896 2988, email maria.osullivan@tcd.ie

oily fish, meat, eggs and some fortified produce. Sunlight is the major source of vitamin D₃ for human subjects. In the skin, UVB rays promote cleavage of 7-dehydrocholesterol (provitamin D₃) into previtamin D₃, which, in turn, is converted by a thermal process to vitamin D₃. Regardless of the source, vitamin D is hydroxylated twice, first in the liver, followed by the kidney. The latter hydroxylation generates 1,25(OH)₂D that exerts its actions by binding to a VDR⁽¹⁶⁾. VDR are present on at least thirty different tissues throughout the body, including the intestinal and colonic tissues, circulating immune cells (such as activated lymphocyte T and B cells), monocytes, macrophages and muscle cells⁽⁷⁾. Importantly, many of these non-skeletal tissues also express vitamin D-activating enzymes, thereby permitting local production of 1,25(OH)₂D. Investigations into the role of the VDR and 1,25(OH)₂D in these extra-skeletal tissues has uncovered novel anti-proliferative, anti-inflammatory and immune-modulating effects, which may be relevant to Crohn's disease.

Optimal vitamin D status

The best measure of an individual's vitamin D status is serum 25-hydroxyvitamin D (25(OH)D)^(6,8) which reflects both sunlight exposure and dietary vitamin D intake. The definition of vitamin D deficiency remains controversial. At present there is no target level set for people with Crohn's disease beyond recommendations for the general, healthy population. The US Institute of Medicine define deficiency as <30 nmol/l, and use 40 and 50 nmol/l to define the estimated average requirement and recommended daily allowance respectively with intakes of 15 µg (600 IU) vitamin D₃/d recommended for adults and children, a tolerable upper intake level of 100 µg (4000 IU)/d and a no observed adverse effect level of 250 µg (10 000 IU) vitamin D₃/d⁽¹⁷⁾. The US Endocrine Society's Clinical Practice Guideline suggests 75 nmol/l as a cut-off for adequacy and intakes of 37.5–50 µg (1500–2000 IU) vitamin D₃/d to achieve this concentration. Irrespective of the cut-off applied (30, 50 or 75 nmol/l), several studies have reported a high prevalence of vitamin D insufficiency and deficiency in established IBD cases (Table 1) and in 80 % of new Crohn's disease diagnoses⁽⁹⁾. In paediatric cases, 25 % of patients have severe deficient levels⁽¹⁸⁾ (Table 1).

Vitamin D toxicity

Vitamin D toxicity is a rare clinical syndrome of both hypervitaminosis D and hypercalcaemia. Clinical symptoms of vitamin D toxicity include nausea, vomiting, dehydration, muscle weakness, lethargy and confusion⁽¹⁹⁾. An upper toxic level of 250 nmol/l is frequently cited in the literature,^(20,21) however, toxicity may not occur until 25(OH)D levels exceed 500 nmol/l⁽²²⁾ or even 750 nmol/l⁽²³⁾. Data on vitamin D toxicity derives mainly from studies involving healthy cohorts. A study in 340 healthy school children⁽²⁴⁾ showed that administration of 350 µg (14 000 IU) vitamin D₃/week for 1 year was safe and brought the mean 25(OH)D concentrations to 90 (SD 55) nmol/l. Measurements conducted in adults

with a constant sun exposure (Puerto-Rican farmers) revealed serum 25(OH)D levels which were often between 100 and 200 nmol/l, while their calcium status was normal⁽²⁵⁾. In Crohn's disease, Jorgensen *et al.*⁽¹⁵⁾ supplemented forty-six patients with 30 µg (1200 IU) vitamin D₃/d and levels increased to 96 (SD 27) nmol/l without any side-effects such as hypercalcaemia after 12 months of treatment. In a smaller study (*n* 18), 125 µg (5000 IU) vitamin D₃/d increased 25(OH)D concentrations to 112.5 (SD 47.5) nmol/l without safety concerns⁽²⁶⁾. Currently 50 µg (2000 IU) vitamin D₃/d is regarded as acceptable and can be taken without medical supervision⁽²⁷⁾, although most clinical trials in Crohn's disease do monitor patients tolerance to supplementation regardless of the dose used as part of the study protocol.

Factors influencing vitamin D levels in Crohn's disease

Several factors predict vitamin D deficiency in Crohn's disease including; longer disease duration, higher Crohn's disease activity index (CDAI) scores, C-reactive protein levels, poor nutrition status, smoking^(28–31), small bowel involvement⁽³¹⁾ and resection⁽³²⁾, non-Caucasian ethnicity⁽³³⁾, sunlight exposure, impaired conversion of vitamin D to its active metabolite, increased catabolism and increased excretion due to steatorrhea.

In Crohn's disease dietary intakes and supplemental intakes appear inadequate for achieving sufficient 25(OH)D status. Less than half (43 %) of the patients are consumers of a vitamin D supplement, with multivitamin preparations being the most common form reported providing on average 5.6 µg (5–10 µg); 225 IU (200–400 IU) vitamin D daily. Moreover, for bone health, present guidelines suggest intakes of 20 µg (800 IU)/d⁽¹¹⁾ which may or may not result in 25(OH)D concentrations ≥75 nmol/l. Studies have indicated intakes of 30, 50 or 125 µg (1200, 2000 or 5000 IU)/d may be required to achieve levels ≥75 nmol/l, depending on baseline levels^(15,26,34).

Diet in Crohn's disease provides approximately 1.0 µg/d (95 % CI 0.6, 1.9)^(35,36) with the main food sources being oily fish (38 %), followed by eggs (27 %)⁽³⁵⁾. Despite being low, dietary intakes in Crohn's disease are comparable with population intakes^(29,37,38). Poor dietary intakes may also be hindered by reduced absorption. Vitamin D is absorbed in the proximal small intestine, particularly in the jejunum⁽³⁹⁾. The effect on vitamin D status due to small bowel involvement is uncertain. In a small study of twelve Crohn's disease patients with a terminal ileum resection a decline in vitamin D absorption correlating with the length of the resection was observed⁽⁴⁰⁾. Conversely Ulitsky *et al.*⁽⁴¹⁾ reported no difference in vitamin D levels between those with a resection *v.* no resection.

Whereas most of the predictors of low serum 25(OH)D in Crohn's disease are consistent throughout the literature, the effect of Crohn's disease activity on the vitamin D status is not confirmed. Some studies have reported no difference in 25(OH)D-based disease activity,^(31,42)

Table 1. Prevalence of suboptimal vitamin D status in inflammatory bowel disease in patients with active and quiescent disease

Author	Year	Cohort	Disease status (remission/active)	Country	% with 25(OH)D levels
Siffledeen <i>et al.</i> ⁽²⁸⁾	2003	242 CD	Not reported	Canada	<25 nmol/l 8
Tajika <i>et al.</i> ⁽¹²⁸⁾	2004	33 CD	Active and remission	Japan	27
Ulitsky <i>et al.</i> ⁽⁴¹⁾	2011	403 CD	Active and remission	Wisconsin, USA	11
Alkhouiri <i>et al.</i> ^{(18)*}	2013	61 IBD	Active	Buffalo, USA	25
Jahnsen <i>et al.</i> ⁽¹²⁹⁾	2002	60 CD, 60 UC	Active and remission	Oslo, Norway	<30 nmol/l 27 in CD, 15 in UC
Yang <i>et al.</i> ⁽²⁶⁾	2013	18 CD	Active	Pennsylvania	52
Wingate <i>et al.</i> ^{(130)*}	2014	83 CD	Remission	Canada	16
Sentongo <i>et al.</i> ^{(131)*}	2002	112 CD	Not reported	USA	<40 nmol/l 16
Siffledeen <i>et al.</i> ⁽²⁸⁾	2003	242 CD	Not reported	Alberta, Canada	22
Pappa <i>et al.</i> ⁽¹³²⁾	2006	94 CD, 36 UC	Not reported	Boston, USA	35
Laakso <i>et al.</i> ^{(10)*}	2012	49 UC, 28 CD	65 % – remission	Helsinki, Finland	30
Wingate <i>et al.</i> ⁽¹³⁰⁾	2014	83 CD	Remission	Canada	33
McCarthy <i>et al.</i> ⁽²⁹⁾	2005	44 CD	Not reported	Cork, Ireland	<50 nmol/l 50
Gilman <i>et al.</i> ⁽³¹⁾	2006	58 CD	48 % – remission	Cork, Ireland	50
Vagianos <i>et al.</i> ⁽¹³³⁾	2007	84 CD	62 % – remission	Canada	46
Fu <i>et al.</i> ⁽¹³⁴⁾	2012	40 CD	46 % – remission	Canada	37
Ananthkrishnan <i>et al.</i> ⁽¹³⁵⁾	2013	1763 CD, 1454 UC	Remission and active disease	USA	32
Nic Suibhne <i>et al.</i> ⁽³⁵⁾	2012	81 CD	Remission	Ireland	63
Garg <i>et al.</i> ⁽¹³⁶⁾	2013	40 CD	55 % – remission	Melbourne, Australia	23
Grunbaum <i>et al.</i> ⁽¹³⁷⁾	2013	34 CD	Remission/mild activity	Canada	29
Abraham <i>et al.</i> ⁽¹³⁸⁾	2014	105 CD, 61UC	Not reported	Texas	23
Wingate <i>et al.</i> ⁽¹³⁰⁾	2014	83 CD	Remission	Canada	33
Vagianas <i>et al.</i> ⁽¹³³⁾	2007	84 CD	62 % – remission	Mantioba, Canada	<75 nmol/l 70
Ulitsky <i>et al.</i> ⁽⁴¹⁾	2011	403 CD, 101 UC	Active and remission	Milwaukee, Wisconsin	50
Garg <i>et al.</i> ⁽¹³⁶⁾	2013	40 CD	55 % – remission	Melbourne, Australia	58
Hassan <i>et al.</i> ⁽⁴²⁾	2013	26 CD, 34 UC	59 % – remission	Iran	95
Grunbaum <i>et al.</i> ⁽¹³⁷⁾	2013	34 CD	Remission/mild activity	Montreal, Canada	50
Abraham <i>et al.</i> ⁽¹³⁸⁾	2014	105 CD, 61UC	Not reported	Texas	60
Wingate <i>et al.</i> ⁽¹³⁰⁾	2014	83 CD	Remission	Canada	79
de Bruyn <i>et al.</i> ⁽³³⁾	2014	101 CD	Not reported	The Netherlands	81
Dumitrescu <i>et al.</i> ⁽¹³⁹⁾	2014	14 CD	Active and remission	Romania	79

CD, Crohn's disease; IBD, inflammatory bowel disease; UC, ulcerative colitis; 25(OH)D, 25-hydroxyvitamin D.

* Paediatric studies.

whereas Jorgensen *et al.* reported low levels were associated with active disease⁽⁴³⁾. A clear trend of decreasing 25(OH)D from remission (64 nmol/l) to mild disease (49 nmol/l) and moderately active disease (21 nmol/l) ($P < 0.01$) was reported⁽⁴³⁾. A recent study confirmed these findings insofar as patients with active Crohn's disease had lower 25(OH)D levels than those in clinical remission; this measurement was independent of season or reported supplement use⁽⁴⁴⁾. There also appears to be wide variation in the absorption of vitamin D in Crohn's disease; for example, Farraye *et al.*⁽⁴⁵⁾ reported that even in quiescent disease ability to absorb vitamin D is reduced by an average of 30 % in comparison with normal subjects after supplementation with 1250 µg (50 000 IU) vitamin D₂. Whether or not the outcome would have been similar had vitamin D₃ been used remains to be seen.

In symptomatic/active disease cholestyramine may also be prescribed to reduce post-resectional diarrhoea. It also reduces bile acids, which are required for vitamin D absorption and may induce vitamin D malabsorption.

Protein losing enteropathy is a condition which can arise in severe disease and can result in the loss of vitamin D-binding protein along with the vitamin D bound to it⁽⁴⁶⁾. Moreover, genetic variants in vitamin D hydroxylation and transport may also contribute substantially to both the development of vitamin D insufficiency and poor response to supplementation⁽⁴⁷⁾.

Beyond diet, sunlight and casual UVB exposure is the main source of vitamin D for most of the population. However, in Crohn's disease immunosuppressive therapy, such as azathioprine and adalimumab, can increase the risk of skin cancer. For this reason patients prescribed such medications are counselled regarding the careful use of sunscreen, which also prevents UVB synthesis of vitamin D. Sun exposure may also have a link to Crohn's disease pre-diagnosis. UVB exposure is often reduced at higher latitudes and coincides with a higher prevalence of autoimmune diseases and colorectal cancer in these regions compared with those more southerly^(48,49) suggesting a possible relationship between latitude and Crohn's disease.

Epidemiological evidence: low vitamin D status and Crohn's disease

Environmental triggers for IBD have been difficult to identify⁽⁵⁰⁾. A German twin cohort study confirmed the strong genetic element to IBD, yet concordance rates between monozygotic twins are nonetheless low (35 % for Crohn's disease and 16 % for ulcerative colitis). This suggests important environmental interactions with disease-inducing genes⁽⁵¹⁾. One potential environmental risk factor is the UVB exposure. Recently a link between latitude and incidence rates of Crohn's disease has been identified in a large prospective study⁽⁵²⁾. By tracking the location and lifestyle information of approximately 175 000 female American nurses biennially over 20 years, the authors detected a greater increase in the incidence rates of Crohn's disease and ulcerative colitis the farther subjects lived from the equator. At age 30 years, living in southern latitudes was associated with a roughly halved risk of developing Crohn's disease and approximately a 40 % reduced risk of developing ulcerative colitis. Similarly Ananthakrishnan *et al.*⁽¹²⁾ found that women with a higher serum vitamin D level had a significantly reduced risk of Crohn's disease (hazard ratio: 0.38) suggesting a protective effect of vitamin D sufficiency.

In Europe an evident north-south gradient of incidence and prevalence also exists⁽⁵³⁻⁵⁵⁾. For example, low sunlight exposure was associated with an increased incidence of Crohn's disease in France and no association with ulcerative colitis⁽⁵⁶⁾. Migration of populations who live near the equator to countries of greater latitude also increases the rate of Crohn's disease^(57,58). More recently, Limketkai *et al.*⁽⁵⁹⁾ reported that lower UV exposure is associated with greater rates of hospitalisation, prolonged hospitalisation and the need for bowel surgery in IBD. Further studies are needed to determine if this association is causal and also the role of other environmental factors that might explain these findings such as pollutants, diet and commensal or pathogenic microorganisms.

Vitamin D and immune function in Crohn's disease: experimental data

Vitamin D appears to have an important role in innate immunity^(14,60). For example, human cathelicidin antimicrobial peptide and beta defensins are antimicrobial peptides of the innate immune system, which are expressed by the gastrointestinal epithelium⁽⁶¹⁾. Antimicrobial peptides protect against bacterial invasion⁽⁶²⁾ and human cathelicidin antimicrobial peptide is important in maintaining and re-establishing intestinal barrier integrity⁽⁶³⁾ and in the healing of human intestinal epithelial cells⁽⁶³⁾. Moreover *in vitro* studies have shown that 1,25(OH)₂D can induce the expression of the gene encoding human cathelicidin antimicrobial peptide⁽⁶⁴⁾. However, the largest body of experimental evidence for an immunoregulatory role for vitamin D in IBD concerns the adaptive T-cell response. Several types of

T-cells are important for the regulation of homeostasis in the gastrointestinal tract and either induce or suppress IBD. The VDR and 1,25(OH)₂D inhibit Th1 and Th17 functions by suppressing the production of particular cytokines^(13,65,66) which restores gastrointestinal homeostasis post infection or chemical injury. In addition, 1,25(OH)₂D stimulates dendritic cell production of IL-10, and T-cell levels of CTLA-4 (an inhibitory co-stimulatory signal), which further enhances its anti-inflammatory effect⁽⁶⁷⁾.

Vitamin D and intestinal permeability in Crohn's disease: experimental data

Animal studies have shown that vitamin D may be linked to Crohn's disease severity and the function of the epithelial barrier. Vitamin D deficiency increased symptoms of several experimental models of IBD⁽⁶⁸⁾ and VDR deficiency increased susceptibility of mice to colitis^(69,70). Conversely treatment with 1,25(OH)₂D improves IBD symptoms and blocks the progression of colitis in mice^(65,70,71).

Vitamin D may also function on the epithelial barrier. Epithelial cells are connected by intercellular junctions, comprising tight junctions and adherens junctions⁽⁷²⁾. Patients with Crohn's disease have increased small intestine permeability⁽⁷³⁾ resulting in part from defects in these junctions. Compromised barrier function in Crohn's disease has been associated with inflammation, dysbiosis⁽⁷⁴⁾, disease pathogenesis and as a predictor of clinical relapse^(75,76). Evidence suggests that vitamin D increases tight junction proteins and enhances gut mucosal healing post-injury⁽⁷⁷⁾. For example, following exposure to dextran sulphate sodium, a chemical which induces colitis, the VDR knock out mice were unable to maintain the integrity of the epithelial barrier^(69,78) and had lower expression of tight junction proteins than in wild-type mice⁽⁷⁷⁻⁷⁹⁾. As a result of reduced tight junction proteins, vitamin D-deficient and VDR knock out mice had increased gut permeability compared with vitamin D-sufficient wild-type mice⁽⁷⁸⁾. Whilst the basic science supports a role for vitamin D in Crohn's disease as reviewed elsewhere⁽⁸⁰⁾, further work is required to establish if this translates to human studies.

Observational studies: association between vitamin D levels, disease activity and surgery in Crohn's disease

Whilst epidemiological, animal and experimental data are promising the full possible range of effects of vitamin D in Crohn's disease are unknown, as are the optimal level(s) for inducing them. Observational studies which have focused on vitamin D and its effect on clinical markers such as CDAI (a research tool used to quantify the symptoms of patients with Crohn's disease) and inflammatory markers have been inconclusive. In cross-sectional IBD cohort studies El-Matary *et al.*⁽⁸¹⁾ and Hassan *et al.*⁽⁴²⁾ reported no association between 25(OH)D and CDAI. CDAI levels <150 are indicative

of remission, whereas levels above that suggest active disease. The mean 25(OH)D in these two studies were 66.7 (SD 27.3) nmol/l and 32.7 (SD 28.3) nmol/l, respectively. The cohorts included both Crohn's disease and ulcerative colitis patients and the sample sizes were small. Another cross-sectional study exclusive to Crohn's disease (n 34) reported a significant inverse association between 25(OH)D and CDAI with mean concentrations of 53.5 (SD 27) nmol/l⁽⁸²⁾. Similar findings were reported by Ulitsky *et al.*⁽⁴¹⁾ who observed greater disease activity in those with lower 25(OH)D levels (Table 2).

Almost two-thirds of patients with Crohn's disease will eventually require surgery as part of their clinical course. Ananthakrishnan *et al.*⁽⁸³⁾ reported that 25(OH)D levels >50 nmol/l in Crohn's disease were associated with fewer surgeries and hospitalisations compared with those with levels below this threshold. A more aggressive disease course and need for surgery among those with vitamin D deficiency was also seen in a South Asian cohort⁽⁸⁴⁾. Overall, despite limitations inherent in cross-sectional studies, such as mixed cohorts of ulcerative colitis and Crohn's disease, a reduced spread of vitamin D levels, different methods of data analysis, role of causality and various primary outcome measures, most of these studies suggest positive correlations between vitamin D and Crohn's disease-related outcomes (Table 2).

Clinical studies; association between 25-hydroxyvitamin D levels, disease activity and relapse in Crohn's disease

Only a small number of intervention studies have examined the effects of vitamin D supplementation in a clinical trial setting in IBD (Table 3). Two studies have reported positive associations with disease activity. The first, a prospective open label study compared supplementation with active vitamin D (alfacalcidol) to 25µg (1000 IU) vitamin D₃ (cholecalciferol) in Crohn's disease⁽⁸⁵⁾. After 6 weeks alfacalcidol treatment resulted in a significant decrease in CDAI scores and C-reactive protein levels, as well as improvement in quality of life (QoL) scores. In spite of this at 12 months there were no significant differences between the groups with respect to these variables⁽⁸⁵⁾. The primary aim of the present study was to examine the effects on bone metabolism and not disease activity; moreover, the paper did not report the 25(OH)D levels obtained by the groups, which may have not been in the therapeutic range at 12 months. Yang *et al.*⁽²⁶⁾ titrated vitamin D₃ intake until such a point serum levels were ≥100 nmol/l (commonly requiring 125µg (5000 IU)/d) and reported significant improvements in CDAI with a mean reduction in CDAI from 230 (SD 74) to 118 (SD 66; $P < 0.0001$). This may suggest a minimum level of 100 nmol/l is required to exert a significant effect on disease severity but further research is warranted. Whilst promising these studies were open label trials and therefore have their inherent limitations. A double-blind randomised placebo-controlled study assessed the effectiveness of vitamin D₃ supplementation in preventing clinical relapse. In comparison with the placebo group, oral vitamin D₃ supplementation of

30µg (1200 IU)/d for 12 months reduced the risk of relapse from 29 to 13 % at 1 year ($P = 0.056$)⁽¹⁵⁾. This difference in relapse was not statistically significant and merits further work (Table 3).

The current authors previously examined the effects of vitamin D supplementation on intestinal permeability as measured by the lactulose : mannitol ratio and sucrose excretion which indicates small bowel permeability⁽⁸⁶⁾. In a double-blind placebo-controlled study 27 Crohn's disease patients were randomised to 50µg (2000 IU)/d vitamin D₃ or placebo. At follow-up (3 months) mean (95 % CI) 25(OH)D levels were as expected significantly higher in the vitamin D group 91.6 (75.5–107.6) nmol/l than in the placebo group 40.4 (30.4–50.4) nmol/l ($P < 0.001$). At 3 months, there was a significant increase in lactulose : mannitol ratio ($P = 0.010$) and sucrose excretion ($P = 0.030$) in the controls, but these parameters were unchanged in the vitamin D group, suggesting that 25(OH)D levels ≥75 nmol/l may preserve intestinal integrity.

Clinical studies; association between 25-hydroxyvitamin D levels and muscle function

Compared with healthy controls in Crohn's disease skeletal muscle mass and strength are reduced^(87–89) and muscle fatigue is increased⁽⁹⁰⁾. Fatigue is a major concern in Crohn's disease^(91–94) with two of five patients reporting that it negatively impacts their QoL, even in remission⁽⁹⁵⁾. Reasons for this may include elevated pro-inflammatory factors such as TNF α and IL-6^(96,97) which are associated with lower muscle mass and strength in elderly populations^(98,99), poor nutrition, physical inactivity and prolonged corticosteroid therapy⁽⁸⁹⁾. The underlying mechanisms of how vitamin D might improve muscle are poorly understood; however, several lines of evidence support a role of vitamin D in muscle health. First, proximal muscle weakness is a prominent feature of vitamin D deficiency⁽¹⁰⁰⁾ in addition to diffuse muscle pain and gait impairments such as a waddling way of walking⁽¹⁰¹⁾. Secondly, skeletal muscle is a major reservoir of 25(OH)D⁽¹⁰²⁾; however, whilst it was previously thought that VDR were abundantly expressed in muscle cells with roles myogenesis and contractility this is currently under debate⁽¹⁰³⁾. Although vitamin D supplementation increases muscle strength and balance in some populations for example in the elderly⁽¹⁰⁴⁾ data in Crohn's disease are not as widely available. In a cross-sectional study, van Landenberg *et al.*⁽¹⁰⁵⁾ reported that high 25(OH)D and physical activity may protect against reduced muscle mass⁽⁹⁰⁾. Conversely Salacinski *et al.*⁽¹⁰⁶⁾ were unable to show a relationship between 25(OH)D levels and muscle strength in Crohn's disease. Although they did show that those with higher 25(OH)D levels (≥100 nmol/l) exhibited greater muscle strength (normalised to body weight) than those with lower levels (≤80 nmol/l) suggesting perhaps optimal effects on muscle function with levels ≥100 nmol/l; however, this is tentative data.

The current authors previously reported the results of a 3-month randomised, double-blind intervention study in quiescent Crohn's disease (n 27)⁽³⁴⁾. Patients were

Table 2. Observational studies of the association between 25-hydroxyvitamin D (25(OH)D) status and disease related outcomes in inflammatory bowel disease (IBD)

Author	Study design, n	Location	Outcome	Result	25(OH)D (nmol/l)	Association
Joseph <i>et al.</i> ⁽⁸²⁾	Cross-sectional 34 CD	India	Disease activity (HBI)	Disease activity negatively correlated with 25(OH)D	Mean level: 53.5 (sd 27) nmol/l (correlation coefficient: 0.484)	Positive
Hassan <i>et al.</i> ⁽⁴²⁾	Cross-sectional - 26 CD - 34 UC	Iran	Disease activity (CDAI)	25(OH)D had no association with disease activity	Mean level: 32.8 (sd 28.3) nmol/l	Nil
El-Matary <i>et al.</i> ⁽⁸¹⁾	Cross-sectional - 39 CD - 21 UC	UK	Disease activity (Paediatric CDAI/ Paediatric UCAI)	25(OH)D had no association with disease activity	Mean level: 66.7 (sd 27.3) nmol/l	Nil
Ulitsky <i>et al.</i> ⁽⁴¹⁾	Retrospective - 403 CD - 101 UC	USA	Disease activity - (HBI)	25(OH)D >75 nmol/l was associated with less disease activity in CD but not UC	Levels >75 nmol/l v. >50 nmol/l were associated with less disease activity (-2.2, 95 % CI -4.1, -0.3) in CD	Positive
Ananthakrishnan <i>et al.</i> ⁽¹²⁾	Prospective - 1763 CD - 1454 UC	USA	IBD related surgeries and hospitalisations	25(OH)D >50 nmol/l was associated with less risk of surgery and hospitalisations in CD	25(OH)D >50 nmol/l was associated with less surgery (OR 1.8, 95 % CI 1.2, 2.5) and hospitalisations (OR 2.1, 95 % CI 1.6, 2.7) in CD	Positive
Garg <i>et al.</i> ⁽¹³⁶⁾	Prospective - 40 CD - 31 UD - 23 controls	Australia	Fecal calprotectin (µg/g) CRP (mg/g)	25(OH)D negatively correlated with calprotectin in CD	Mean in CD: 70(95% CI 61, 78) nmol/l Mean in UC :70(95% CI 58, 81) nmol/l	Positive
Ananthakrishnan <i>et al.</i> ⁽¹⁴⁰⁾	3188 IBD patients	USA	CDI	25(OH)D >50 nmol/l were less likely to develop CDI (OR 2.27, 95 % CI 1.16, 4.44) v. individuals with vitamin D <50 nmol/l	Mean 25(OH)D in those who developed CDI; 51 nmol/l and in those who did not develop CDI; 67.8 nmol/l	Positive

CD, Crohn's disease; UC, ulcerative colitis; IBD, inflammatory bowel disease; HBI, Harvey Bradshaw index; CDAI, Crohn's disease activity index; CDI, *Clostridium difficile* infection; CRP, C-reactive protein; UCAI, ulcerative colitis activity index.

Table 3. Intervention studies; relationship between 25-hydroxyvitamin D (25(OH)D) and outcomes in Crohn's disease

Author	Design	Intervention and duration	Outcome	Result	25(OH)D	Association
Miheller <i>et al.</i> ⁽⁸⁵⁾	Open label study n 37 Inactive Crohn's disease	0.5 µg alfacalcidol/d or 50µg (1000 IU) vitamin D ₃ /d for 12 months	CDAI	Mean CDAI decreased from 69 to 57. Mean CRP (mg/l) decreased from 15.8 to 7.8 nmol/l ($P < 0.05$) in patients treated with alfacalcidol	Not reported	Positive
Yang <i>et al.</i> ⁽²⁶⁾	Open label study Prospective n 18 Mild-moderate CD	125µg (5000 IU) vitamin D ₃ /d for 24 weeks	CDAI QoL	Vitamin D supplementation reduced CDAI scores from 230 (74) to 118 (66) ($P < 0.0001$) QoL improved from 156 (24) to 178 (22) ($P < 0.0006$)	112.5 (sd 47.5) nmol/l	Positive
Jorgensen <i>et al.</i> ⁽¹⁵⁾	Randomised double-blind placebo-controlled study, n 94	30µg (1200 IU) vitamin D ₃ /d 12 months	Relapse in a 12 month period	No significant difference in relapse between groups ($P = 0.056$)	96 (sd 27) nmol/l in the treated group	Negative

CD, Crohn's disease, CDAI, Crohn's disease activity index; QoL, quality of life.

randomised to either 50µg (2000 IU)/d vitamin D₃ or placebo and the primary outcome measures included changes in hand-grip strength, a proxy measure for muscle strength. Post-intervention, both dominant and non-dominant hand-grip strength were significantly higher in the vitamin D-treated group compared with the controls. In the same study group, we also assessed changes

in fatigue and QoL⁽³⁴⁾. At 3 months, patients who achieved 25(OH)D levels ≥ 75 nmol/l had significantly higher QoL compared with patients below this cut-off ($P = < 0.0001$). In line with this, significantly less fatigue was experienced in those with 25(OH)D levels ≥ 75 nmol/l compared with those below this cut-off, as assessed by question 2 of the IBD questionnaire.

In a cross-sectional study of 504 IBD patients (403 Crohn's disease patients and 101 ulcerative colitis patients) vitamin D deficiency (<50 nmol/l) was associated with lower QoL in Crohn's disease but not ulcerative colitis;⁽⁴¹⁾ however, muscle function and fatigue were not measured in the present study. Another intervention study⁽²⁶⁾ also showed improved QoL scores following vitamin D supplementation ($P < 0.0004$), particularly when serum concentrations were ≥ 100 nmol/l⁽²⁶⁾. This was paralleled with significant improvements in CDAI scores; however, muscle strength was not measured in this study.

Vitamin D and cancer in Crohn's disease

More recently, associations between vitamin D status and cancer have been examined. Epidemiological studies suggest an increased risk of and mortality from cancer in northern latitudes with reduced UVB exposure, an association possibly mediated by vitamin D⁽¹⁰⁷⁾. Furthermore, prospective cohorts have demonstrated an inverse association between 25(OH)D and cancers of the colon, breast and prostate^(108–111) with one intervention study reporting a reduced risk of cancer by 60%⁽¹¹²⁾ with levels >80 nmol/l. Ananthakrishnan *et al.*⁽¹²⁾ looked at data from 2809 patients with IBD and a median plasma 25(OH)D level of 65 nmol/l. During a median follow-up period of 11 years, 196 patients (7%) developed cancer, excluding non-melanoma skin cancer (forty-one cases of colorectal cancer). Patients with vitamin D deficiency had an increased risk of cancer (adjusted OR, 1.82; 95% CI 1.25, 2.65) compared with those with sufficient levels. Each 1–2.5 nmol/l increase in plasma 25(OH)D was associated with an 8% reduction in risk of colorectal cancer (OR, 0.92; 95% CI 0.88, 0.96). The mean plasma 25(OH)D in patients who subsequently developed cancer was 12.5 nmol/l lower than in those who did not develop cancer (57 *v.* 69 nmol/l; $P < 0.0001$). They also reported a statistically significant inverse association for lung cancer (OR, 0.95; 95% CI 0.90, 0.99). However, the study has its limitations; for example, the confounding impact of inflammation and low BMI on low 25(OH)D status was not reported and there was a lack of information on screening practices and on smoking.

Conclusion

Vitamin D insufficiency in IBD remains common. Consensus expert opinion has suggested 25(OH)D levels of 75–100 nmol/l may provide optimal benefits for musculoskeletal and cancer outcomes⁽²⁰⁾ and levels of 100–175 nmol/l for optimal immune effects⁽¹¹³⁾. The data reviewed here show evidence of positive associations with levels ≥ 75 nmol/l in Crohn's disease, and further possible associations with levels ≥ 100 nmol/l but such associations need validation with well-designed randomised controlled trials. These include associations with CDAI, muscle function, fatigue, QoL, maintenance of epithelial barrier

function, decreased hospitalisations, reduced risk of surgery and cancer. In terms of dosage required to achieve these levels 20–25 μg (800–1000 IU)/d vitamin D₃ appears sufficient to achieve a serum level of 50 nmol/l, and between 25 and 100 μg (1000 and 4000 IU)/d to bring levels beyond 75 nmol/l (on average 50 μg (2000 IU)/d is required for this purpose^(114–123)). In the present study of Crohn's disease patients, we found that 50 μg (2000 IU)/d increased mean 25(OH)D levels to 91.6 (95% CI 75.5, 107.6) nmol/l over winter months, which was significantly higher than levels in the placebo group 40.4 (95% CI 30.4, 50.4) nmol/l ($P < 0.001$)⁽³⁴⁾. To obtain 25(OH)D status ≥ 100 nmol/l in Crohn's disease, 125 μg (5000 IU)/d may be required⁽²⁶⁾. This is the lower end of what is considered the 'physiological' zone of 75–200 nmol/l, the range which corresponds to the serum levels observed in outdoor workers^(25,124,125) as well as in traditionally living populations in East Africa⁽¹²⁶⁾. This zone is far below the toxic zone, which appears to be located above the 400 nmol/l serum level⁽¹²⁷⁾. To conclude there are many unanswered clinical questions regarding the role of vitamin D in Crohn's disease such as: (1) what is the optimal role of vitamin D supplementation as a therapeutic modality in Crohn's disease; (2) what is the effect of disease activity and resection on circulating 25(OH)D concentrations; (3) what is the level with which a plateau effect is observed in terms of relapse prevention/immune augmentation, if any. Additional well-designed and executed randomised double-blind placebo-controlled trials which investigate 25(OH)D levels are required to address these questions.

Financial Support

T. R. is supported by a fellowship from the Irish Research Council (IRC) and the Sarah Purser research award from Trinity College, Dublin.

Conflict of Interest

None.

Authorship

T. R. and M. O'S. wrote the manuscript and approved the final draft of the submitted manuscript.

References

1. Xavier RJ & Podolsky DK (2007) Unravelling the pathogenesis of inflammatory bowel disease. *Nature* **448**, 427–434.
2. Abraham C & Cho JH (2009) Inflammatory bowel disease. *N Engl J Med* **361**, 2066–2078.
3. Khor B, Gardet A & Xavier RJ (2011) Genetics and pathogenesis of inflammatory bowel disease. *Nature* **474**, 307–317.
4. Jostins L, Ripke S, Weersma RK *et al.* (2012) Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. *Nature* **491**, 119–124.

5. Ananthakrishnan AN (2013) Environmental triggers for inflammatory bowel disease. *Curr Gastroenterol Rep* **15**, 302.
6. Holick MF (2007) Vitamin D deficiency. *N Engl J Med* **357**, 266–281.
7. Holick MF (2004) Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. *Am J Clin Nutr* **80**, 6 Suppl., 1678S–1688S.
8. Rosen CJ (2011) Clinical practice. Vitamin D insufficiency. *N Engl J Med* **364**, 248–254.
9. Leslie WD, Miller N, Rogala L *et al.* (2008) Vitamin D status and bone density in recently diagnosed inflammatory bowel disease: the Manitoba IBD Cohort Study. *Am J Gastroenterol* **103**, 1451–1459.
10. Laakso S, Valta H, Verkasalo M *et al.* (2012) Impaired bone health in inflammatory bowel disease: a case-control study in 80 pediatric patients. *Calcif Tissue Int* **91**, 121–130.
11. Mowat C, Cole A, Windsor A *et al.* (2011) Guidelines for the management of inflammatory bowel disease in adults. *Gut* **60**, 571–607.
12. Ananthakrishnan AN, Khalili H, Higuchi LM *et al.* (2012) Higher predicted vitamin D status is associated with reduced risk of Crohn's disease. *Gastroenterology* **142**, 482–489.
13. Cantorna MT & Mahon BD (2004) Mounting evidence for vitamin D as an environmental factor affecting autoimmune disease prevalence. *Exp Biol Med (Maywood)* **229**, 1136–1142.
14. Cantorna MT, Zhu Y, Froicu M *et al.* (2004) Vitamin D status, 1,25-dihydroxyvitamin D₃, and the immune system. *Am J Clin Nutr* **80**, 6 Suppl., 1717S–1720S.
15. Jørgensen SP, Agnholt J, Glerup H *et al.* (2010) Clinical trial: vitamin D₃ treatment in Crohn's disease – a randomized double-blind placebo-controlled study. *Aliment Pharmacol Ther* **32**, 377–383.
16. Raftery T, O'Morain CA & O'Sullivan M (2012) Vitamin D: new roles and therapeutic potential in inflammatory bowel disease. *Curr Drug Metab* **13**, 1294–1302.
17. Institute of Medicine (2010) Report Brief: Dietary Reference Intakes for Calcium and Vitamin D.
18. Alkhouri RH, Hashmi H, Baker RD *et al.* (2013) Vitamin and mineral status in patients with inflammatory bowel disease. *J Pediatr Gastroenterol Nutr* **56**, 89–92.
19. Blank S, Scanlon KS, Sinks TH *et al.* (1995). An outbreak of hypervitaminosis D associated with the overfortification of milk from a home-delivery dairy. *Am J Public Health* **85**, 656–659.
20. Souberbielle JC, Body JJ, Lappe JM *et al.* (2010) Vitamin D and musculoskeletal health, cardiovascular disease, autoimmunity and cancer: recommendations for clinical practice. *Autoimmun Rev* **9**, 709–715.
21. Vieth R (1999). Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. *Am J Clin Nutr* **69**, 842–856.
22. Vieth R (2006) Critique of the considerations for establishing the tolerable upper intake level for vitamin D: critical need for revision upwards. *J Nutr* **136**, 1117–1122.
23. Jones G (2008) Pharmacokinetics of vitamin D toxicity. *Am J Clin Nutr* **88**, 582S–586S.
24. Maalouf J, Nabulsi M, Vieth R *et al.* (2008) Short- and long-term safety of weekly high-dose vitamin D₃ supplementation in school children. *J Clin Endocrinol Metab* **93**, 2693–2701.
25. Haddock L & Corcino J, Vazques MD (1982) V. 25(OH)D serum levels in the normal Puerto Rican population and in subjects with tropical sprue and parathyroid disease. *Puerto Rico Health Sci J* **1**, 85–91.
26. Yang L, Weaver V, Smith JP *et al.* (2013) Therapeutic effect of vitamin d supplementation in a pilot study of Crohn's patients. *Clin Transl Gastroenterol* **4**, e33.
27. Hanley DA, Cranney A, Jones G *et al.* (2010) Vitamin D in adult health and disease: a review and guideline statement from Osteoporosis Canada. *CMAJ* **182**, E610–E618.
28. Siffledeen JS, Siminoski K, Steinhart H *et al.* (2003) The frequency of vitamin D deficiency in adults with Crohn's disease. *Can J Gastroenterol* **17**, 473–478.
29. McCarthy D, Duggan P, O'Brien M *et al.* (2005) Seasonality of vitamin D status and bone turnover in patients with Crohn's disease. *Aliment Pharmacol Ther* **21**, 1073–1083.
30. Harries AD, Brown R, Heatley RV *et al.* (1985) Vitamin D status in Crohn's disease: association with nutrition and disease activity. *Gut* **26**, 1197–1203.
31. Gilman J, Shanahan F & Cashman KD (2006) Determinants of vitamin D status in adult Crohn's disease patients, with particular emphasis on supplemental vitamin D use. *Eur J Clin Nutr* **60**, 889–896.
32. Driscoll RH, Meredith SC, Sitrin M *et al.* (1982) Vitamin D deficiency and bone disease in patients with Crohn's disease. *Gastroenterology* **83**, 1252–1258.
33. de Bruyn JR, van Heeckeren R, Ponsioen CY *et al.* (2014) Vitamin D deficiency in Crohn's disease and healthy controls: a prospective case-control study in the Netherlands. *J Crohns Colitis* **8**, 1287–1273.
34. Raftery T, Lee C, Cox G *et al.* (2013) Supplemental vitamin D in quiescent Crohn's disease – effects on quality of life, fatigue and muscle strength: results from a double blind placebo controlled study. *Proc Nutr Soc* **72**, OCE3, E177.
35. Suibhne TN, Cox G, Healy M *et al.* (2012) Vitamin D deficiency in Crohn's disease: prevalence, risk factors and supplement use in an outpatient setting. *J Crohns Colitis* **6**, 182–188.
36. Vogelsang H, Klamert M, Resch H *et al.* (1995) Dietary vitamin D intake in patients with Crohn's disease. *Wien Klin Wochenschr* **107**, 578–581.
37. Filippi J, Al-Jaouni R, Wiroth JB *et al.* (2006) Nutritional deficiencies in patients with Crohn's disease in remission. *Inflam Bowel Dis* **12**, 185–191.
38. Bin CM, Flores C, Alvares-da-Silva MR *et al.* (2010) Comparison between handgrip strength, subjective global assessment, anthropometry, and biochemical markers in assessing nutritional status of patients with Crohn's disease in clinical remission. *Dig Dis Sci* **55**, 137–144.
39. Hollander D & Truscott TC (1976) Mechanism and site of small intestinal uptake of vitamin D₃ in pharmacological concentrations. *Am J Clin Nutr* **29**, 970–975.
40. Leichtmann GA, Bengoa JM, Bolt MJ *et al.* (1991) Intestinal absorption of cholecalciferol and 25-hydroxycholecalciferol in patients with both Crohn's disease and intestinal resection. *Am J Clin Nutr* **54**, 548–552.
41. Ulitsky A, Ananthakrishnan AN, Naik A *et al.* (2011) Vitamin D deficiency in patients with inflammatory bowel disease: association with disease activity and quality of life. *JPEN J Parenter Enteral Nutr* **35**, 308–316.
42. Hassan V, Hassan S, Seyed-Javad P *et al.* (2013) Association between serum 25 (OH) vitamin D concentrations and inflammatory bowel diseases (IBDs) activity. *Med J Malaysia* **68**, 34–38.
43. Jørgensen SP, Hvas CL, Agnholt J *et al.* (2013) Active Crohn's disease is associated with low vitamin D levels. *J Crohns Colitis* **7**, e407–e413.

44. Ham M, Longhi MS, Lahiff C *et al.* (2014) Vitamin D levels in adults with Crohn's disease are responsive to disease activity and treatment. *Inflamm Bowel Dis* **20**, 856–860.
45. Farraye FA, Nimitphong H, Stucchi A *et al.* (2011) Use of a novel vitamin D bioavailability test demonstrates that vitamin D absorption is decreased in patients with quiescent Crohn's disease. *Inflamm Bowel Dis* **17**, 2116–2121.
46. Mouli VP & Ananthakrishnan AN (2014) Review article: vitamin D and inflammatory bowel diseases. *Aliment Pharmacol Ther* **39**, 125–136.
47. Wang TJ, Zhang F, Richards JB *et al.* (2010) Common genetic determinants of vitamin D insufficiency: a genome-wide association study. *Lancet* **376**, 180–188.
48. Simpson S, Blizzard L, Otahal P *et al.* (2011) Latitude is significantly associated with the prevalence of multiple sclerosis: a meta-analysis. *J Neurol Neurosurg Psychiatry* **82**, 1132–1141.
49. Peyrin-Biroulet L, Oussalah A & Bigard MA (2009) Crohn's disease: the hot hypothesis. *Med Hypotheses* **73**, 94–96.
50. Frolkis A, Dieleman LA, Barkema H *et al.* (2013) Environment and the inflammatory bowel diseases. *Can J Gastroenterol* **27**, e18–e24.
51. Spehlmann ME, Begun AZ, Burghardt J *et al.* (2008) Epidemiology of inflammatory bowel disease in a German twin cohort: results of a nationwide study. *Inflamm Bowel Dis* **14**, 968–976.
52. Khalili H, Huang ES, Ananthakrishnan AN *et al.* (2012) Geographical variation and incidence of inflammatory bowel disease among US women. *Gut* **61**, 1686–1692.
53. Shivananda S, Lennard-Jones J, Logan R *et al.* (1996) Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). *Gut* **39**, 690–697.
54. Loftus EV & Sandborn WJ (2002) Epidemiology of inflammatory bowel disease. *Gastroenterol Clin North Am* **31**, 1–20.
55. Schultz M & Butt AG (2012) Is the north to south gradient in inflammatory bowel disease a global phenomenon?. *Expert Rev Gastroenterol Hepatol* **6**, 445–447.
56. Burisch J, Pedersen N, Cukovic-Cavka S *et al.* (2013) Environmental factors in a population-based inception cohort of inflammatory bowel disease patients in Europe – An ECCO-EpiCom study. *J Crohns Colitis* **8**, 607–616.
57. Pinsk V, Lemberg DA, Grewal K *et al.* (2007) Inflammatory bowel disease in the South Asian pediatric population of British Columbia. *Am J Gastroenterol* **102**, 1077–1083.
58. Sewell JL, Yee HF & Inadomi JM (2010) Hospitalizations are increasing among minority patients with Crohn's disease and ulcerative colitis. *Inflamm Bowel Dis* **16**, 204–207.
59. Limketkai BN, Bayless TM, Brant SR *et al.* (2014) Lower regional and temporal ultraviolet exposure is associated with increased rates and severity of inflammatory bowel disease hospitalisation. *Aliment Pharmacol Ther* **40**, 508–517.
60. Cantorna MT & Mahon BD (2005). D-hormone and the immune system. *J Rheumatol Suppl* **76**, 11–20.
61. Jäger S, Stange EF & Wehkamp J (2013) Inflammatory bowel disease: an impaired barrier disease. *Langenbecks Arch Surg* **398**, 1–12.
62. Tollin M, Bergman P, Svenberg T *et al.* (2003) Antimicrobial peptides in the first line defence of human colon mucosa. *Peptides* **24**, 523–530.
63. Otte JM, Zdebek AE, Brand S *et al.* (2009) Effects of the cathelicidin LL-37 on intestinal epithelial barrier integrity. *Regul Pept* **156**, 104–117.
64. Gombart AF, Borregaard N & Koeffler HP (2005) Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1,25-dihydroxyvitamin D₃. *FASEB J* **19**, 1067–1077.
65. Daniel C, Sartory NA, Zahn N *et al.* (2008) Immune modulatory treatment of trinitrobenzene sulfonic acid colitis with calcitriol is associated with a change of a T helper (Th) 1/Th17 to a Th2 and regulatory T cell profile. *J Pharmacol Exp Ther* **324**, 23–33.
66. Tang J, Zhou R, Luger D *et al.* (2009) Calcitriol suppresses antiretinal autoimmunity through inhibitory effects on the Th17 effector response. *J Immunol* **182**, 4624–4632.
67. Jeffery LE, Burke F, Mura M *et al.* (2009) 1,25-Dihydroxyvitamin D3 and IL-2 combine to inhibit T cell production of inflammatory cytokines and promote development of regulatory T cells expressing CTLA-4 and FoxP3. *J Immunol* **183**, 5458–5467.
68. Cantorna MT (2012) Vitamin D, multiple sclerosis and inflammatory bowel disease. *Arch Biochem Biophys* **523**, 103–106.
69. Froicu M & Cantorna MT (2007) Vitamin D and the vitamin D receptor are critical for control of the innate immune response to colonic injury. *BMC Immunol* **8**, 5.
70. Froicu M, Weaver V, Wynn TA *et al.* (2003) A crucial role for the vitamin D receptor in experimental inflammatory bowel diseases. *Mol Endocrinol* **17**, 2386–2392.
71. Cantorna MT, Munsick C, Bemiss C *et al.* (2000) 1,25-Dihydroxycholecalciferol prevents and ameliorates symptoms of experimental murine inflammatory bowel disease. *J Nutr* **130**, 2648–2652.
72. Henderson P, van Limbergen JE *et al.* (2011) Function of the intestinal epithelium and its dysregulation in inflammatory bowel disease. *Inflamm Bowel Dis* **17**, 382–395.
73. Marchiando AM, Graham WV & Turner JR (2010) Epithelial barriers in homeostasis and disease. *Annu Rev Pathol* **5**, 119–144.
74. Cantorna MT, McDaniel K, Bora S *et al.* (2014) Vitamin D, immune regulation, the microbiota, and inflammatory bowel disease. *Exp Biol Med (Maywood)* **239**, 1524–1530.
75. D'Inca R, Di Leo V, Corrao G *et al.* (1999) Intestinal permeability test as a predictor of clinical course in Crohn's disease. *Am J Gastroenterol* **94**, 2956–2960.
76. Wyatt J, Vogelsang H, Hübl W *et al.* (1993) Intestinal permeability and the prediction of relapse in Crohn's disease. *Lancet* **341**, 1437–1439.
77. Kong J, Zhang Z, Musch MW *et al.* (2008) Novel role of the vitamin D receptor in maintaining the integrity of the intestinal mucosal barrier. *Am J Physiol Gastrointest Liver Physiol* **294**, G208–G216.
78. Ooi JH, Li Y, Rogers CJ *et al.* (2013) Vitamin D regulates the gut microbiome and protects mice from dextran sodium sulfate-induced colitis. *J Nutr* **143**, 1679–1686.
79. Zhang Y, Leung DY, Richers BN *et al.* (2012) Vitamin D inhibits monocyte/macrophage proinflammatory cytokine production by targeting MAPK phosphatase-1. *J Immunol* **188**, 2127–2135.
80. Hewison M (2010) Vitamin D and the immune system: new perspectives on an old theme. *Endocrinol Metab Clin North Am* **39**, 365–379; table of contents.
81. El-Matary W, Sikora S & Spady D (2011) Bone mineral density, vitamin D, and disease activity in children newly diagnosed with inflammatory bowel disease. *Dig Dis Sci* **56**, 825–829.
82. Joseph AJ, George B, Pulimood AB *et al.* (2009) 25 (OH) vitamin D level in Crohn's disease: association with sun exposure & disease activity. *Indian J Med Res* **130**, 133–137.

83. Ananthakrishnan AN, Cagan A, Gainer VS *et al.* (2013) Normalization of plasma 25-hydroxy vitamin D is associated with reduced risk of surgery in Crohn's disease. *Inflamm Bowel Dis* **19**, 1921–1927.
84. Boyd CA & Limdi JK (2013) Vitamin D deficiency and disease outcomes in South Asian patients with IBD. *Dig Dis Sci* **58**, 2124–2125.
85. Miheller P, Muzes G, Hritz I *et al.* (2009) Comparison of the effects of 1,25 dihydroxyvitamin D and 25 hydroxyvitamin D on bone pathology and disease activity in Crohn's disease patients. *Inflamm Bowel Dis* **15**, 1656–1662.
86. Raftery T, Martineau A, Greiller C *et al.* (2013) Does vitamin D supplementation impact plasma cathelicidin, human beta defensin 2 and intestinal permeability in stable Crohn's disease? – Results from a randomised, double blind placebo controlled study. *Proc Nutr Soc* **72**, OCE3, E176.
87. Schneider SM, Al-Jaouni R, Filippi J *et al.* (2008) Sarcopenia is prevalent in patients with Crohn's disease in clinical remission. *Inflamm Bowel Dis* **14**, 1562–1568.
88. Wiroth JB, Filippi J, Schneider SM *et al.* (2005) Muscle performance in patients with Crohn's disease in clinical remission. *Inflamm Bowel Dis* **11**, 296–303.
89. Geerling BJ, Badart-Smook A, Stockbrügger RW *et al.* (1998) Comprehensive nutritional status in patients with long-standing Crohn disease currently in remission. *Am J Clin Nutr* **67**, 919–926.
90. van Langenberg DR, Della Gatta P, Warmington SA *et al.* (2014) Objectively measured muscle fatigue in Crohn's disease: correlation with self-reported fatigue and associated factors for clinical application. *J Crohns Colitis* **8**, 137–146.
91. Jelsness-Jorgensen LP, Bernklev T, Henriksen M *et al.* (2012) Chronic fatigue is associated with increased disease-related worries and concerns in inflammatory bowel disease. *World J Gastroenterol* **18**, 445–452.
92. Casati J, Toner BB, de Rooy EC, Drossman DA *et al.* (2000) Concerns of patients with inflammatory bowel disease: a review of emerging themes. *Dig Dis Sci* **45**, 26–31.
93. Drossman DA, Patrick DL, Mitchell CM *et al.* (1989) Health-related quality of life in inflammatory bowel disease. Functional status and patient worries and concerns. *Dig Dis Sci* **34**, 1379–1386.
94. Maunder RG, de Rooy EC, Toner BB *et al.* (1997) Health-related concerns of people who receive psychological support for inflammatory bowel disease. *Can J Gastroenterol* **11**, 681–685.
95. Minderhoud IM, Oldenburg B, van Dam PS *et al.* (2003) High prevalence of fatigue in quiescent inflammatory bowel disease is not related to adrenocortical insufficiency. *Am J Gastroenterol* **98**, 1088–1093.
96. Reimund JM, Wittersheim C, Dumont S *et al.* (1996) Mucosal inflammatory cytokine production by intestinal biopsies in patients with ulcerative colitis and Crohn's disease. *J Clin Immunol* **16**, 144–150.
97. Cominelli F (2004) Cytokine-based therapies for Crohn's disease—new paradigms. *N Engl J Med* **351**, 2045–2048.
98. Visser M, Pahor M, Taaffe DR *et al.* (2002) Relationship of interleukin-6 and tumor necrosis factor-alpha with muscle mass and muscle strength in elderly men and women: the Health ABC Study. *J Gerontol A Biol Sci Med Sci* **57**, M326–M332.
99. Schaap LA, Pluijm SM, Deeg DJ *et al.* (2006) Inflammatory markers and loss of muscle mass (sarcopenia) and strength. *Am J Med* **119**, e9–e17.
100. Al-Shoha A, Qiu S, Palnitkar S *et al.* (2009) Osteomalacia with bone marrow fibrosis due to severe vitamin D deficiency after a gastrointestinal bypass operation for severe obesity. *Endocr Pract* **15**, 528–533.
101. Schott GD & Wills MR (1976) Muscle weakness in osteomalacia. *Lancet* **1**, 626–629.
102. Mawer EB, Backhouse J, Holman CA *et al.* (1972). The distribution and storage of vitamin D and its metabolites in human tissues. *Clin Sci* **43**, 413–431.
103. Boillon R, Gielen E & Vanderschueren D (2014) Vitamin D receptor and vitamin D action in muscle. *Endocrinology* **155**, 3210–3213.
104. Pfeifer M, Begerow B, Minne HW *et al.* (2009) Effects of a long-term vitamin D and calcium supplementation on falls and parameters of muscle function in community-dwelling older individuals. *Osteoporos Int* **20**, 315–322.
105. van Langenberg DR, Gatta PD, Hill B *et al.* (2013) Delving into disability in Crohn's disease: dysregulation of molecular pathways may explain skeletal muscle loss in Crohn's disease. *J Crohns Colitis* **8**, 626–634.
106. Salacinski AJ, Regueiro MD, Broeder CE *et al.* (2013) Decreased neuromuscular function in Crohn's disease patients is not associated with low serum vitamin D levels. *Dig Dis Sci* **58**, 526–533.
107. Wacker M & Holick MF (2013) Vitamin D – effects on skeletal and extraskeletal health and the need for supplementation. *Nutrients* **5**, 111–148.
108. Feskanich D, Ma J, Fuchs CS *et al.* (2004) Plasma vitamin D metabolites and risk of colorectal cancer in women. *Cancer Epidemiol Biomarkers Prev* **13**, 1502–1508.
109. Giovannucci E (2007) Strengths and limitations of current epidemiologic studies: vitamin D as a modifier of colon and prostate cancer risk. *Nutr Rev* **65**, Pt 2, S77–S79.
110. Giovannucci E (2009) Vitamin D and cancer incidence in the Harvard cohorts. *Ann Epidemiol* **19**, 84–88.
111. Giovannucci E, Liu Y, Rimm EB *et al.* (2006) Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. *J Natl Cancer Inst* **98**, 451–459.
112. Lappe JM, Travers-Gustafson D, Davies KM *et al.* (2007) Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. *Am J Clin Nutr* **85**, 1586–1591.
113. Cannell JJ & Hollis BW (2008) Use of vitamin D in clinical practice. *Altern Med Rev* **13**, 6–20.
114. Heaney RP, Davies KM, Chen TC *et al.* (2003) Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. *Am J Clin Nutr* **77**, 204–210.
115. Heaney RP, Horst RL, Cullen DM *et al.* (2009) Vitamin D3 distribution and status in the body. *J Am Coll Nutr* **28**, 252–256.
116. Grant WB & Holick MF (2005) Benefits and requirements of vitamin D for optimal health: a review. *Altern Med Rev* **10**, 94–111.
117. Hollis BW (2005) Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: implications for establishing a new effective dietary intake recommendation for vitamin D. *J Nutr* **135**, 317–322.
118. Bischoff-Ferrari HA, Willett WC, Orav EJ *et al.* (2012) A pooled analysis of vitamin D dose requirements for fracture prevention. *N Engl J Med* **367**, 40–49.
119. Hall LM, Kimlin MG, Aronov PA *et al.* (2010) Vitamin D intake needed to maintain target serum 25-hydroxyvitamin D concentrations in participants with low sun exposure and dark skin pigmentation is substantially higher than current recommendations. *J Nutr* **140**, 542–550.



120. Vieth R (2006) What is the optimal vitamin D status for health? *Prog Biophys Mol Biol* **92**, 26–32.
121. Whiting SJ & Calvo MS (2010) Correcting poor vitamin D status: do older adults need higher repletion doses of vitamin D3 than younger adults? *Mol Nutr Food Res* **54**, 1077–1084.
122. Garrett-Mayer E, Wagner CL, Hollis BW *et al.* (2012) Vitamin D3 supplementation (4000 IU/d for 1 y) eliminates differences in circulating 25-hydroxyvitamin D between African American and white men. *Am J Clin Nutr* **96**, 332–336.
123. Holick MF (2012) Vitamin D: extraskeletal health. *Rheum Dis Clin North Am* **38**, 141–160.
124. Barger-Lux MJ & Heaney RP (2002) Effects of above average summer sun exposure on serum 25-hydroxyvitamin D and calcium absorption. *J Clin Endocrinol Metab* **87**, 4952–4956.
125. Azizi E, Pavlotsky F, Kudish A *et al.* (2012) Serum levels of 25-hydroxy-vitamin D3 among sun-protected outdoor workers in Israel. *Photochem Photobiol* **88**, 1507–1512.
126. Luxwolda MF, Kuipers RS, Kema IP *et al.* (2012) Traditionally living populations in East Africa have a mean serum 25-hydroxyvitamin D concentration of 115 nmol/l. *Br J Nutr* **108**, 1557–1561.
127. Hathcock JN, Shao A, Vieth R *et al.* (2007) Risk assessment for vitamin D. *Am J Clin Nutr* **85**, 6–18.
128. Tajika M, Matsuura A, Nakamura T *et al.* (2004) Risk factors for vitamin D deficiency in patients with Crohn's disease. *J Gastroenterol* **39**, 527–533.
129. Jahnsen J, Falch JA, Mowinckel P *et al.* (2002) Vitamin D status, parathyroid hormone and bone mineral density in patients with inflammatory bowel disease. *Scand J Gastroenterol* **37**, 192–199.
130. Wingate KE, Jacobson K, Issenman R *et al.* (2014) 25-Hydroxyvitamin D concentrations in children with Crohn's disease supplemented with either 2000 or 400 IU daily for 6 months: a randomized controlled study. *J Pediatr* **164**, 860–865.
131. Sentongo TA, Semaio EJ, Stettler N *et al.* (2002) Vitamin D status in children, adolescents, and young adults with Crohn disease. *Am J Clin Nutr* **76**, 1077–1081.
132. Pappa HM, Gordon CM, Saslowsky TM *et al.* (2006) Vitamin D status in children and young adults with inflammatory bowel disease. *Pediatrics* **118**, 1950–1961.
133. Vagianos K, Bector S, McConnell J *et al.* (2007) Nutrition assessment of patients with inflammatory bowel disease. *JPEN J Parenter Enteral Nutr* **31**, 311–319.
134. Fu YT, Chatur N, Cheong-Lee C *et al.* (2012) Hypovitaminosis D in adults with inflammatory bowel disease: potential role of ethnicity. *Dig Dis Sci* **57**, 2144–2148.
135. Ananthakrishnan AN, Cheng SC, Cai T *et al.* (2013) Association between reduced plasma 25-hydroxy vitamin D and increased risk of cancer in patients with inflammatory bowel diseases. *Clin Gastroenterol Hepatol* **12**, 821–827.
136. Garg M, Rosella O, Lubel JS *et al.* (2013) Association of circulating vitamin D concentrations with intestinal but not systemic inflammation in inflammatory bowel disease. *Inflamm Bowel Dis* **19**, 2634–2643.
137. Grunbaum A, Holcroft C, Heilpern D *et al.* (2013) Dynamics of vitamin D in patients with mild or inactive inflammatory bowel disease and their families. *Nutr J* **12**, 145.
138. Abraham BP, Prasad P & Malaty HM (2014) Vitamin D deficiency and corticosteroid use are risk factors for low bone mineral density in inflammatory bowel disease patients. *Dig Dis Sci* **59**, 1878–1884.
139. Dumitrescu G, Mihai C, Dranga M *et al.* (2014) Serum 25-hydroxyvitamin D concentration and inflammatory bowel disease characteristics in Romania. *World J Gastroenterol* **20**, 2392–2396.
140. Ananthakrishnan AN, Cheng SC, Cai T *et al.* (2014) Association between reduced plasma 25-hydroxy vitamin d and increased risk of cancer in patients with inflammatory bowel diseases. *Clin Gastroenterol Hepatol* **12**, 821–827.